Ocugen (OCGN) Short-term Investments (2017 - 2023)

Ocugen's (OCGN) quarterly Short-term Investments came in at $8.5 million in Q1 2023, down 36.71% on a QoQ basis from $13.4 million in Q4 2022.

Analysis

Ocugen (OCGN) Short-term Investments (2017 - 2023) Analysis & Trends

Ocugen (OCGN) has 4 years of Short-term Investments data on file, last reported at $8.5 million in Q1 2023.

Quarterly Short-term Investments changed N/A year-over-year to $8.5 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $8.5 million (changed N/A YoY) and the FY2022 annual result came in at $13.4 million, changed N/A from the prior year.
Short-term Investments retreated to $8.5 million in Q1 2023, from $13.4 million in the prior quarter.
In the past five years, Short-term Investments ranged from a high of $13.4 million in Q4 2022 to a low of $5.0 million in Q1 2021.
A 3-year average of $7.4 million and a median of $5.0 million in 2021 frame the typical range for Short-term Investments.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn
8	Royalty Pharma	28.45 Bn	27.61 Bn	-
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn
10	Ocugen	458.91 Mn	358.81 Mn	-

Historic Data

Download Data